Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study

Belli, L.; Berenguer, Marina; Cortesi, P.A.; Facchetti, Rita; Strazzabosco, Mario; Rockenschaub, S.; Martini, Silvia; Morelli, Cristina; Donato, F.; Volpes, Riccardo; Pageaux, G.-P.; Coilly, Audrey; Fagiuoli, S.; Berlakovich, Gabriela; Monico, Sara; Vinaixa, Carmen; Polak, W.; Duvoux, Christophe

doi:10.1016/s0168-8278(17)30339-2

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…173,[175][176][177][178] Similar results have been reported in real-world studies. [179][180][181][182][183][184] Patients with Child-Pugh B cirrhosis benefited more from viral clearance in terms of adverse event-free survival at 15 months than those with Child-Pugh C cirrhosis. 179 Treatment of HCV infection pre-transplant in patients awaiting liver transplantation has 2 complementary goals: preventing liver graft infection after transplantation and stabilising or improving liver function before transplantation.…”

Section: Treatment Of Patients With Decompensated (Child-pugh B or C)mentioning

confidence: 99%

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

818

632

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.

show abstract

Section: Treatment Of Patients With Decompensated (Child-pugh B or C)mentioning

confidence: 99%

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Pawlotsky¹,

Negro²,

Aghemo³

et al. 2020

Journal of Hepatology

818

632

View full text Add to dashboard Cite

show abstract

“…No HCC occurred. 121 In a French cohort study, including 18 transplant centres with a mean follow-up of 68 weeks (range: 12-95 weeks), 18% of patients (14/77) were delisted and 16% (12/77) improved. 57 In a similar Spanish study, 24% (29/122) of patients were delisted after DAA-based therapy.…”

Section: Patients With Decompensated Cirrhosis No Hcc With An Indicmentioning

confidence: 99%

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Buonomo¹,

Scotto²,

Coppola³

et al. 2020

Medicine

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in Anti-HCV antibodies are detectable in serum or plasma by enzyme immunoassay (EIA) in the vast majority of patients with HCV infection, but EIA results may be negative in early acute Journal of Hepatology 2018 vol. 69 j 461-511 q Clinical practice guidelines panel: Chair: Jean-Michel Pawlotsky; EASL governing board representative: Francesco Negro; Panel members:

show abstract

“…Patients with decompensated cirrhosis with or without an indication for LT should be treated in order to achieve improvement in liver function and survival. For patients awaiting LT, the goal is not only to improve liver function, but also to prevent liver graft infection after LT [27, 28].…”

Section: Hepatitis C Virus Infectionmentioning

confidence: 99%

Abnormal Liver Blood Tests: Hepatologist Approach

Krstić

Mijač

Tomašević

et al. 2021

Dig Dis

View full text Add to dashboard Cite

Background: Available data suggest that the prevalence of chronic liver disease (CLD) and primary liver cancer is rising in Europe and represents a major public health problem. Predictions are showing that these trends will continue to rise in the upcoming years. Summary: Alcohol-related liver disease, nonalcohol fatty liver disease, and viral hepatitis B and hepatitis C are the leading causes of liver cirrhosis and primary liver cancer in Europe. Drug-induced liver injury represents a major cause of acute hepatitis, while liver transplantation is the second most common solid organ transplantation in the world. Patients with CLD have increasing rates of hospitalization, longer hospital stays, and more adverse outcomes compared to the other chronic conditions. Direct targeting of risk factors can prevent complications of advanced liver disease and improve outcome. Patients with CLD should be referred to a hepatologist for assessment of the stage of liver disease, for specific treatment and screening for hepatocellular carcinoma. Moreover, patients with unknown etiology of abnormal liver blood tests should be referred to a hepatologist for assessment of liver disease, as well as for prevention and treatment of complications of cirrhosis and/or portal hypertension. Key Messages: CLD is amenable to prevention and treatment, while disease management strategies need to improve in order to reduce the burden of liver disease and deaths due to end-stage liver diseases.

show abstract

Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study

Cited by 5 publications

References 0 publications

EASL recommendations on treatment of hepatitis C: Final update of the series☆

EASL recommendations on treatment of hepatitis C: Final update of the series☆

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Abnormal Liver Blood Tests: Hepatologist Approach

Contact Info

Product

Resources

About